Acasă › Cancer hematologic › Massachusetts › Boston
Studii clinice pentru Cancer hematologic în Boston, MA
25 studii pentru Cancer hematologic caută participanți în și în jurul orașului Boston (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
În curs de recrutare
- Massachusetts General Hospital, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
În curs de recrutareFaza 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
În curs de recrutareStudiu observațional
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
În curs de recrutare
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
În curs de recrutareFaza 2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Dana Farber Cancer Institute, Boston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
În curs de recrutareFaza 2
- Brigham and Women's Hospital, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
În curs de recrutareVoluntari sănătoși bineveniți
- Dana-Farber Cancer Institute, Boston
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
În curs de recrutareFaza 3
- Tufts Medical Center, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
În curs de recrutareStudiu observațional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
IVIG for Infection Prevention After CAR-T-Cell Therapy
În curs de recrutareFaza 2
- Massachusetts General Hospital Cancer Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
În curs de recrutareStudiu observațional
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
În curs de recrutareFaza 1
- Dana Farber Cancer Institute, Boston
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
În curs de recrutare
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
În curs de recrutare
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
În curs de recrutareFaza 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
În curs de recrutare
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
În curs de recrutare
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
În curs de recrutareFaza 1
- Dana-Farber Cancer Institute, Boston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
În curs de recrutareFaza 1
- Dana-Farber Cancer Institute, Boston
Studii pentru Cancer hematologic în alte orașe
- Houston, TX46 studii
- New York City, NY26 studii
- Washington, DC19 studii
- Baltimore, MD18 studii
- Seattle, WA18 studii
- Los Angeles, CA17 studii
- Durham, NC16 studii
- Chicago, IL15 studii
- Philadelphia, PA14 studii
- Atlanta, GA13 studii
- Nashville, TN13 studii
- Edison, NJ13 studii
Alte studii în Boston
- Cancer de sân111 studii
- Cancer pulmonar cu celule non-pătrate90 studii
- Cancer (toate tipurile)86 studii
- Cancer colorectal63 studii
- Cancer metastatic63 studii
- Cancer pulmonar62 studii
- Cancer ovarian61 studii
- Cancer de prostată59 studii
- Depresie52 studii
- Cancer endometrial50 studii
- Insuficiență cardiacă44 studii
- Leucemie mieloasă acută44 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.